Brookline Capital Management Comments on Envoy Medical, Inc.’s Q3 2024 Earnings (NASDAQ:COCH)

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at Brookline Capital Management issued their Q3 2024 earnings per share estimates for Envoy Medical in a research note issued on Monday, October 14th. Brookline Capital Management analyst T. Bussian forecasts that the company will post earnings of ($0.27) per share for the quarter. Brookline Capital Management has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.22) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.56) EPS.

Separately, Ascendiant Capital Markets upped their price objective on Envoy Medical from $8.50 to $8.75 and gave the company a “buy” rating in a research note on Tuesday, September 3rd.

Envoy Medical Trading Up 7.9 %

NASDAQ:COCH opened at $2.72 on Wednesday. Envoy Medical has a one year low of $0.75 and a one year high of $11.46. The business’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $3.17.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Monday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.08 million.

Hedge Funds Weigh In On Envoy Medical

An institutional investor recently bought a new position in Envoy Medical stock. Virtu Financial LLC purchased a new stake in shares of Envoy Medical, Inc. (NASDAQ:COCH) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 14,045 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Envoy Medical as of its most recent filing with the SEC. 8.59% of the stock is owned by institutional investors and hedge funds.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.